Executive Activity at Halozyme Therapeutics Signals Confidence Amid Strong Financial Reporting
Halozyme Therapeutics CEO, Helen Torley, recently executed a sale of company stock totaling approximately $3.37 million after exercising vested options. This executive activity occurred while the company reported strong financial performance for Q1 2026, surpassing analyst expectations. Despite recent selling by top management and noted industry he…